Condition

Large Cell Neuroendocrine Carcinoma of the Lung

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 11 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials11
Recruiting3
Common interventions15
Lead sponsors shown10
Advertisement

Clinical trials

11 shown
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid TumorsNCT07006727 · 2025-10-16
RECRUITING
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsNCT06814496 · 2025-09-08
RECRUITING
FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and PlatinumNCT06393816 · 2024-06-13
RECRUITING
A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the LungNCT07561645 · 2026-09-01
NOT_YET_RECRUITING
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based ChemotherapyNCT06736418 · 2025-03-10
ACTIVE_NOT_RECRUITING
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung CancerNCT05680922 · 2023-07-26
ACTIVE_NOT_RECRUITING
A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the LungNCT05470595 · 2022-01-18
ACTIVE_NOT_RECRUITING
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLCNCT04010357 · 2020-01-13
COMPLETED
Atezolizumab in Large Cell Neuroendocrine CarcinomaNCT06049966 · 2019-11-01
COMPLETED
Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine CarcinomaNCT03901378 · 2019-10-02
WITHDRAWN
uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the LungNCT02755675 · 2016-04-01
UNKNOWN

Trial status mix

ACTIVE_NOT_RECRUITING3
RECRUITING3
COMPLETED2
NOT_YET_RECRUITING1
UNKNOWN1
WITHDRAWN1

Phase mix

PHASE27
PHASE15
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.